JP2007099731A - Health functional composition - Google Patents
Health functional composition Download PDFInfo
- Publication number
- JP2007099731A JP2007099731A JP2005294699A JP2005294699A JP2007099731A JP 2007099731 A JP2007099731 A JP 2007099731A JP 2005294699 A JP2005294699 A JP 2005294699A JP 2005294699 A JP2005294699 A JP 2005294699A JP 2007099731 A JP2007099731 A JP 2007099731A
- Authority
- JP
- Japan
- Prior art keywords
- health functional
- composition obtained
- functional composition
- liquefied
- lactic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 230000036541 health Effects 0.000 title claims abstract description 16
- 210000000593 adipose tissue white Anatomy 0.000 claims abstract description 9
- 210000002966 serum Anatomy 0.000 claims abstract description 8
- 201000004384 Alopecia Diseases 0.000 claims abstract description 7
- 208000000044 Amnesia Diseases 0.000 claims abstract description 7
- 208000031091 Amnestic disease Diseases 0.000 claims abstract description 7
- 208000024963 hair loss Diseases 0.000 claims abstract description 7
- 230000003676 hair loss Effects 0.000 claims abstract description 7
- 230000007935 neutral effect Effects 0.000 claims abstract description 7
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- 238000009825 accumulation Methods 0.000 claims abstract description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 64
- 235000014655 lactic acid Nutrition 0.000 claims description 32
- 239000004310 lactic acid Substances 0.000 claims description 32
- 238000000855 fermentation Methods 0.000 claims description 17
- 230000004151 fermentation Effects 0.000 claims description 17
- 241000894006 Bacteria Species 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 235000007164 Oryza sativa Nutrition 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 235000009566 rice Nutrition 0.000 claims description 6
- 238000007912 intraperitoneal administration Methods 0.000 claims description 5
- 244000061456 Solanum tuberosum Species 0.000 claims description 4
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 235000012015 potatoes Nutrition 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 230000004584 weight gain Effects 0.000 claims description 4
- 235000019786 weight gain Nutrition 0.000 claims description 4
- 240000001929 Lactobacillus brevis Species 0.000 claims description 2
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 235000013339 cereals Nutrition 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000013361 beverage Nutrition 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 230000001766 physiological effect Effects 0.000 abstract description 11
- 241000699670 Mus sp. Species 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 8
- 230000006986 amnesia Effects 0.000 abstract description 6
- 241000700159 Rattus Species 0.000 abstract description 5
- 239000007788 liquid Substances 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- 150000002632 lipids Chemical class 0.000 abstract description 3
- 230000037396 body weight Effects 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 241000186660 Lactobacillus Species 0.000 abstract 1
- 229940039696 lactobacillus Drugs 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000209094 Oryza Species 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 235000015278 beef Nutrition 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 235000020083 shōchū Nutrition 0.000 description 4
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 235000013405 beer Nutrition 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 3
- 229960002646 scopolamine Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000003760 tallow Substances 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000004225 Cathepsin B Human genes 0.000 description 2
- 108090000712 Cathepsin B Proteins 0.000 description 2
- 102000004172 Cathepsin L Human genes 0.000 description 2
- 108090000624 Cathepsin L Proteins 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000001399 Kallikrein Human genes 0.000 description 2
- 108060005987 Kallikrein Proteins 0.000 description 2
- 102000002397 Kinins Human genes 0.000 description 2
- 108010093008 Kinins Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 241001303601 Rosacea Species 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007087 memory ability Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 201000004700 rosacea Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- JIWUESGGKYLPPG-UHFFFAOYSA-N 2-[4-[4-(2-hydroxy-4,4-dimethyl-2-morpholin-4-iumyl)phenyl]phenyl]-4,4-dimethyl-2-morpholin-4-iumol Chemical compound C1[N+](C)(C)CCOC1(O)C1=CC=C(C=2C=CC(=CC=2)C2(O)OCC[N+](C)(C)C2)C=C1 JIWUESGGKYLPPG-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 201000004338 pollen allergy Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 235000019992 sake Nutrition 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004071 soot Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000003868 tissue accumulation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Alcoholic Beverages (AREA)
- Non-Alcoholic Beverages (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
Abstract
Description
本発明は、醗酵副産物を乳酸菌で醗酵させた健康機能組成物に関する。 The present invention relates to a health functional composition obtained by fermenting fermentation byproducts with lactic acid bacteria.
穀物、イモ類、糖類などを原料としてこれに酵母と、場合によっては麹あるいは酵素剤を加え、アルコール醗酵させた後に、液部を分離した固体残渣を粕と呼ぶ。アルコール発酵させる酒類としては清酒、焼酎、ビールなどが知られているが、これら酒類製造時に副産物として発生する粕の効能については、いくつか知見がある。 Grains, potatoes, sugars, etc. are used as raw materials, and yeast and, in some cases, koji or an enzyme agent are added thereto. After alcohol fermentation, the solid residue separated from the liquid part is called koji. Sake, shochu, beer, and the like are known as alcoholic fermented alcoholic beverages, but there are some findings about the efficacy of koji produced as a by-product during the production of these alcoholic beverages.
ビール粕については、肉牛、乳牛などの家畜の飼料として用いる他、ビール粕を醗酵させた有機肥料が開発されているが、その生理機能についての報告はない。焼酎粕については、主な廃棄処理方法であった海洋投棄がロンドン条約により禁止され、代替廃棄方法ならびに資源としての有効利用法が検討されており、近年焼酎粕からもろみ酢を製造する方法が開発されている。また、焼酎粕には抗ガン作用、血栓溶解作用があることも報告されている。 Regarding beer lees, in addition to being used as feed for livestock such as beef cattle and dairy cattle, organic fertilizers fermented with beer lees have been developed, but there are no reports on their physiological functions. As for shochu, ocean dumping, which was the main disposal method, was banned by the London Convention, and alternative disposal methods and effective utilization methods as resources have been studied. In recent years, a method for producing moromi vinegar from shochu has been developed. Has been. In addition, it has been reported that shochu has an anticancer action and a thrombolytic action.
一方、清酒の粕(以後単に酒粕と言うこともある)の効果についは以下のようなことが知られている。 On the other hand, the following is known about the effect of sake lees (hereinafter sometimes referred to simply as sake lees).
血糖は膵臓で作られるインスリンにより脂肪細胞に取り込まれ、脂肪に変わってエネルギー源となるが、インスリンの作用が妨げられ、血糖が脂肪細胞に取り込まれずに増えてしまうと糖尿病を発症する。酒粕中にはインスリンと類似の作用を有する物質が含まれており、脂肪の分解を抑制することが明らかとなった。従って、酒粕を摂取することにより糖尿病の予防効果が期待される。 Blood sugar is taken up by fat cells by insulin produced in the pancreas and becomes fat as an energy source. However, when the action of insulin is hindered and blood sugar increases without being taken up by fat cells, diabetes develops. It has been clarified that sake mash contains a substance having an action similar to that of insulin and suppresses the decomposition of fat. Therefore, the effect of preventing diabetes is expected by ingesting sake lees.
血圧の調節系には腎臓から分泌されるレニン及びカリクレインがあり、レニンが血中のタンパク質を分解してアンジオテンシンを作ることにより、血管が収縮されたり交感神経が刺激されたりして血圧が上昇する。一方、カリクレインが、肝臓から分泌されるキノーゲンに作用してキニンを作ることにより血管が拡張し血圧が降下する。ヒトを含む動物にはアンジオテンシン変換酵素が存在し、血圧上昇作用のあるアンジオテンシンの働きを強め、血圧降下作用のあるキニンの働きを弱める。このアンジオテンシン変換酵素を阻害するペプチドが清酒及び酒粕から発見され、これらを高血圧ラットに与えると、ラットの血圧が降下することが確認された。この事から酒粕が高血圧の予防に役立つと期待される。
さらに年齢を重ねると、骨タンパク質分解酵素であるカテプシンLが増え、骨吸収の速度を速め、骨を壊してしまうが、酒粕にはこのカテプシンLの働きを阻止する成分が含まれているため、酒粕が骨粗鬆症の予防に役立つと考えられる。
There are renin and kallikrein secreted from the kidney in the blood pressure regulation system, and renin breaks down proteins in the blood to make angiotensin, which increases blood pressure by constricting blood vessels and stimulating sympathetic nerves. . On the other hand, kallikrein acts on kinogen secreted from the liver to produce kinin, thereby expanding blood vessels and lowering blood pressure. Angiotensin-converting enzyme exists in animals including humans, strengthens the action of angiotensin that has an effect of raising blood pressure, and weakens the action of kinin that has an action of lowering blood pressure. Peptides that inhibit this angiotensin converting enzyme were discovered from sake and sake lees, and it was confirmed that when these were given to hypertensive rats, the blood pressure of the rats decreased. It is expected that sake lees will help prevent high blood pressure.
As the age increases, cathepsin L, a bone proteolytic enzyme, increases the speed of bone resorption and breaks the bone, but sake lees contain ingredients that block the action of cathepsin L. It is thought that rosacea helps prevent osteoporosis.
また、脳梗塞は脳内の血管が詰まることによって起こり、これには心臓など他から血栓が持ち込まれ脳内血管を詰まらせる脳塞栓、脳内の血管自体に動脈硬化が起きて血栓ができる脳血栓がある。血液の塊を溶かすウロキナーゼにより血液がスムースに流れるようになっており、また、血栓を溶かす物質にプラスミノーゲンがある。清酒や酒粕の中には体内でウロキナーゼの合成を促進させる酵素やプラスミノーゲンに働いて血栓を溶かす物質があることが明らかとなった。このことから酒粕が脳梗塞の予防に役立つのではないかと期待されている。 Cerebral infarction is caused by clogging of blood vessels in the brain. This includes cerebral embolism that clogs blood vessels from other places such as the heart, and cerebral thrombus that causes clots due to arteriosclerosis in the blood vessels in the brain. There is. Blood flows smoothly with urokinase, which dissolves blood clots, and plasminogen is a substance that dissolves blood clots. It has been clarified that some sake and sake lees contain enzymes that promote the synthesis of urokinase in the body and substances that act on plasminogen to dissolve thrombus. Therefore, it is expected that sake lees will help prevent cerebral infarction.
心筋に酸素やエネルギーを供給する血管が狭くなって血流が低下したり(狭心症)、血液が流れなくなって心筋への酸素・栄養補給が阻害されたりすると心臓の働きが乱れる(心筋梗塞)。血液中に悪玉コレステロールがあると動脈硬化が起こり、狭心症や心筋梗塞を引き起こす。酒粕には血清や肝臓中の総コレステロールの上昇を抑え、善玉コレステロールを増やす働きがあること、すなわち、悪玉コレステロールを減らす働きがあることが分かった。このことから、酒粕が狭心症、心筋梗塞などの心疾患や動脈硬化の予防に役立つのではないかと期待されている。 When the blood vessels that supply oxygen and energy to the myocardium are narrowed and blood flow is reduced (angina pectoris), or when blood stops flowing and oxygen and nutrient supply to the myocardium is inhibited, myocardial function is disturbed (myocardial infarction) ). If there is bad cholesterol in the blood, arteriosclerosis occurs, causing angina and myocardial infarction. It has been found that sake lees suppress the increase in total cholesterol in the serum and liver and increase good cholesterol, that is, reduce bad cholesterol. Therefore, it is expected that rosacea may be useful for preventing heart diseases such as angina pectoris and myocardial infarction and arteriosclerosis.
アトピー性皮膚炎や花粉アレルギーはカテプシンBという酵素によって作られる免疫グロブリンが原因で引き起こされるアレルギーであると言われている。日本酒や麹の中にはカテプシンBの働きを阻害する物質が含まれていることが分かった。この事から、酒粕がアレルギー体質の改善に役立つのではないかと期待されている。
シミ・ソバカスは皮膚のメラニン色素の沈着によって起こる。アミノ酸の一種であるL−チロシンにチロシナーゼが作用してドーパクロムというメラニン色素前駆物質ができる。ドーパクロムがメラニン色素に変わることにより、シミ・ソバカスができたり、日焼けして皮膚が黒くなったりする。酒粕にはチロシナーゼの働きを阻害する物質が含まれていることが分かった。チロシナーゼが阻害されるとドーパクロムは生成されない。このため、酒粕には美白効果があるものと期待されている。
It is said that atopic dermatitis and pollen allergy are allergies caused by an immunoglobulin produced by an enzyme called cathepsin B. It was found that sake and koji contained substances that inhibit the function of cathepsin B. From this, it is expected that sake lees will help improve allergic constitutions.
Spots and freckles are caused by the deposition of melanin pigment in the skin. Tyrosinase acts on L-tyrosine, which is a kind of amino acid, to produce a melanin pigment precursor called dopachrome. Dopachrome turns into melanin, which can cause spots and freckles, or can be tanned and the skin darkened. It was found that sake lees contain substances that inhibit the action of tyrosinase. When tyrosinase is inhibited, dopachrome is not produced. For this reason, sake lees are expected to have a whitening effect.
このように、酒粕の効用として多くのものが期待されている。しかしながら、これらのいくつかは清酒、麹、酒粕に有効成分が含まれていることを見出したと言う結果があるのみであり、そのことからそれぞれの効果が期待できる、とされているものもある。 Thus, many things are expected as the effects of sake lees. However, some of these have only the result of finding that active ingredients are contained in sake, sake, and sake lees, and there are some that are expected to have their respective effects.
様々な生理活性が期待できる酒粕は素材としては興味深いが、さらなる生理活性を持つ組成物が望まれている。 Sake lees that can be expected to have various physiological activities are interesting as materials, but compositions with further physiological activities are desired.
本発明者らは、酒粕よりも新規な、そして/又は高い生理活性があることが期待される液化仕込み粕に着目し、さらにこれを乳酸菌で発酵させた組成物を用いることにした。鋭意検討の結果、液化粕を乳酸菌で発酵させたものは、酒粕や液化仕込み粕よりもさらに高い様々な生理活性を持つことが分かり、上記課題を解決することができた。 The present inventors focused on a liquefied preparation koji that is newer than liquor and / or expected to have higher physiological activity, and further decided to use a composition obtained by fermenting it with lactic acid bacteria. As a result of intensive studies, it was found that liquefied koji fermented with lactic acid bacteria has various higher physiological activities than sake koji and liquefied koji koji, and the above problems could be solved.
通常の酒粕に替えて液化仕込み粕を用いることにより、また、さらにこれを乳酸菌発酵させることにより、中性脂肪抑制など様々な生理活性を持つ組成物を得ることができ、これを用いれば様々な健康に寄与する組成物となる。 By using a liquefied mash in place of ordinary sake lees and by further fermenting it with lactic acid bacteria, compositions having various physiological activities such as neutral fat suppression can be obtained. The composition contributes to health.
以下、本発明を詳細に記述する。 Hereinafter, the present invention will be described in detail.
近年酒粕のさまざまな機能性が明らかになってきた。例えば、血圧降下、骨粗鬆症の予防、脳梗塞の予防、心筋梗塞の予防、動脈硬化の予防、コレステロール値の低下作用、アレルギー体質の改善、シミの改善、美白効果、などのいろいろな効果が分かってきた。
しかしながら、酒粕そのものを乳酸菌で発酵させて利用するという報告はほとんど見られていない。乳酸菌で発酵させた酒粕には、乳酸菌による酒粕成分の変化、例えばタンパク質の分解による新たなペプチドの生成などによる、さらなる新規な、又は強い生理活性が見られることが期待できる。
In recent years, various functions of sake lees have been revealed. For example, various effects such as lowering blood pressure, prevention of osteoporosis, prevention of cerebral infarction, prevention of myocardial infarction, prevention of arteriosclerosis, action of lowering cholesterol level, improvement of allergic constitution, improvement of spots, whitening effect, etc. have been known. It was.
However, there are few reports of using sake lees themselves fermented with lactic acid bacteria. The sake lees fermented with lactic acid bacteria can be expected to show further new or strong physiological activities due to changes in the sake lees components by lactic acid bacteria, for example, the production of new peptides by protein degradation.
さらに本発明者らは、通常の酒粕とは別の、さらなる効果が期待できる液化液仕込みにより発生する液化粕に着目した。液化液仕込みとは、清酒の仕込みにおいては蒸米を用いるが、液化液仕込みではその代わりに浸漬米をすりつぶし、このスラリー(乳化液)を高温で液化酵素(αアミラーゼ)を加えて処理し、米を液化させてものを仕込み原料として仕込むという方法である。液化液仕込みのアルコール発酵後に上槽(液部と固形部の分離)をした後に残る固形部を液化粕と呼んでいる。液化粕は通常の酒粕に比べてタンパク質、ペプチドを多く含むなどの特徴があり、通常の酒粕とは組成などが異なっている。このため、通常の酒粕とは別の生理活性が期待できる。 Furthermore, the present inventors paid attention to a liquefied lees generated by charging a liquefied liquor that can be expected to have a further effect different from ordinary sake lees. Liquefied liquor preparation uses steamed rice for sake preparation, but instead liquefied liquor is used to grind the soaked rice, and this slurry (emulsion) is treated with liquefied enzyme (α-amylase) at high temperature, This is a method of charging a liquefied material as a charged raw material. The solid part remaining after the upper tank (separation of the liquid part and the solid part) after the alcohol fermentation with the liquefied liquid is called the liquefied soot. A liquefied lees has characteristics such as containing more proteins and peptides than a normal liquor and has a composition different from that of an ordinary liquor. For this reason, physiological activity different from normal sake lees can be expected.
本発明者らはこの液化粕に着目し、さらにこれを乳酸菌により発酵させること(以後これを単に乳酸発酵と呼ぶこともある)により、新たな生理活性が生じるかどうかを検討した。 The present inventors paid attention to this liquefied koji, and further examined whether or not a new physiological activity is produced by fermenting it with lactic acid bacteria (hereinafter, this may be simply referred to as lactic acid fermentation).
乳酸発酵させるための乳酸菌は市販キムチより分離したいくつかの乳酸菌から、液化粕の発酵力及び味覚に最も優れた1株を選択した。この菌を同定したところ、Lactobacillus brevisであることが分かった。 Lactic acid bacteria for lactic acid fermentation were selected from several lactic acid bacteria isolated from commercially available kimchi, and one strain with the best fermenting power and taste of liquefied koji was selected. When this bacterium was identified, it was found to be Lactobacillus brevis.
また、液化粕の乳酸発酵は次のようにして行った。液化粕に水を加えてミキサーで粉砕し、これに前培養していた乳酸菌を接種した。乳酸菌プロテアーゼによるペプチド生成量が最大になる条件として、常温で48時間発酵させた。 Moreover, lactic acid fermentation of the liquefied koji was performed as follows. Water was added to the liquefied koji, pulverized with a mixer, and inoculated with lactic acid bacteria that had been pre-cultured. As a condition for maximizing the amount of peptide produced by lactic acid bacteria protease, fermentation was performed at room temperature for 48 hours.
マウス又はラットで実験を行った結果、乳酸発酵した液化粕(以後これを単に乳酸発酵液化粕と呼ぶこともある)には、体重増加抑制効果、腹腔内白色脂肪組織の蓄積抑制効果、血中脂質(中性脂肪)改善効果、健忘症抑制効果、脱毛抑制効果が見られることがわかった。 As a result of experiments in mice or rats, lactic acid fermented liquefied potatoes (hereinafter sometimes referred to simply as lactic acid fermented liquefied potatoes) have an effect of suppressing weight gain, an inhibitory effect on intraperitoneal white adipose tissue, It was found that a lipid (neutral fat) improving effect, an amnesia suppressing effect, and a hair loss suppressing effect were observed.
以下、実施例を示して本発明をより詳細に説明するが、本発明はこれらの実施例に限定されるものではない。 EXAMPLES Hereinafter, although an Example is shown and this invention is demonstrated in detail, this invention is not limited to these Examples.
体重増加抑制試験
オスの4週齢のC57BL/6Jマウス(黒マウス)を一群3匹で実験を行った。第1群ブランク区は、通常食のCE−2(日本クレア製)のみを与え、第2群コントロール区は50%CE−2に40%フルクトースと10%カゼインを加えたものを与え、第3群テスト区は50%CE−2に40%フルクトースと10%乳酸発酵液化粕を加えたものを与えた。これを10週間、自由摂取条件下で飼育した。カロリーはCE−2が344kcalで、コントロール、テスト区が385kcalと、ほとんど同じであった。自由摂取条件下であったが、摂取量はどの区もほぼ同じであった。その結果の体重変化量を図1に示す。ブランク区に比べ、肥満を誘発させたコントロール区では体重の増加が著しかったが、肥満を誘発させて、さらに乳酸発酵物を加えたテスト区では体重の増加がブランク区とあまり変わらず、乳酸発酵液化粕を加えることにより体重の増加が抑制されることがわかった。
Weight gain suppression test Male 4-week-old C57BL / 6J mice (black mice) were tested in groups of 3 mice. Group 1 blank group gives only CE-2 (manufactured by CLEA Japan) of normal diet, Group 2 control group gives 50% CE-2 plus 40% fructose and 10% casein, The group test group gave 50% CE-2 plus 40% fructose and 10% lactic acid fermentation liquor. This was reared for 10 weeks under free intake conditions. The calorie was 344 kcal for CE-2 and almost the same as 385 kcal for the control and test plots. Although it was under free intake conditions, the intake was almost the same in every section. The resulting change in weight is shown in FIG. Compared with the blank group, the control group that induced obesity showed a significant increase in body weight, but the test group that induced obesity and added lactic acid fermented product did not change much in weight compared to the blank group, and lactic acid fermentation. It was found that weight gain was suppressed by adding liquefied sputum.
腹腔内白色脂肪組織の蓄積抑制試験
実施例1と同じマウス、及び餌を用いて実施例1と同様の試験区を設け、試験開始10週間後にマウスを屠殺した後に解剖し、腹腔内を観察した。その結果、ブランク区に比べ、コントロール区では腹腔内の白色脂肪組織が相当肥大しており、多くの白色脂肪の蓄積が見られたが、乳酸発酵液化粕を加えたテスト区ではブランク区と白色脂肪組織の広がりや量はほとんど変わらず、腹腔内白色脂肪組織の蓄積が抑制されたことがわかった。解剖したマウスの腹腔内の様子を図2に示す。なお、図2中の黒色で囲んだ部分は白色脂肪組織部分を分かりやすく示したものである。
Intraperitoneal white adipose tissue accumulation suppression test The same test section as in Example 1 was provided using the same mice as in Example 1 and food, and the mice were dissected after 10 weeks from the start of the test, and the abdominal cavity was observed. . As a result, white adipose tissue in the abdominal cavity was considerably enlarged in the control group compared with the blank group, and a large amount of white fat was accumulated. It was found that the spread and amount of adipose tissue remained almost unchanged and accumulation of intraperitoneal white adipose tissue was suppressed. A state of the dissected mouse in the abdominal cavity is shown in FIG. In addition, the part enclosed in black in FIG. 2 shows the white adipose tissue part in an easy-to-understand manner.
血中脂質改善試験
4週齢のメスのICRマウスを1群3匹で、与える餌として次の区を設けた。ブランク区:CE−2、コントロール区:CE−2に20%牛脂と10%グルコースと10%カゼインを加えたもの、乳酸発酵液化粕区:CE−2に20%牛脂と10%グルコースと10%乳酸発酵液化粕を加えたもの、未発酵液化粕区:CE−2に20%牛脂と10%グルコースと10%の乳酸発酵させていない液化粕を加えたもの。これらを自由摂取させ、3週間後に全採血を行い、血清中性脂肪を分析した。その結果を図3に示す。コントロール区ではブランク区と比べて中性脂肪はわずかに上昇していたが、乳酸発酵させていない液化粕を加えた区では血清中性脂肪はブランク区と比べて減少しており、乳酸発酵液化粕を添加した区ではさらに大きく血清中性脂肪が減少していた。このことから、液化粕に血清中性脂肪を抑制する効果を有するが、これを乳酸発酵させた液化粕はさらにこの抑制効果を増強させることが分かった。
Blood lipid improvement test Three groups of 4 week-old female ICR mice were provided, and the following section was provided as food to be given. Blank group: CE-2, control group: CE-2 with 20% beef tallow, 10% glucose and 10% casein added, lactic acid fermentation liquefaction sardine group: CE-2 with 20% beef tallow, 10% glucose and 10% Lactic acid fermented liquefied rice cake, unfermented liquefied rice cake: CE-2 with 20% beef tallow, 10% glucose and 10% liquefied rice cake not fermented with lactic acid. These were ad libitum, whole blood was collected after 3 weeks, and serum triglyceride was analyzed. The result is shown in FIG. Neutral fat increased slightly in the control group compared to the blank group, but serum neutral fat decreased in the group with liquefied koji that was not lactic acid fermented compared to the blank group. Serum triglycerides were greatly reduced in the group with addition of sputum. From this, it was found that the liquefied koji has an effect of suppressing serum neutral fat, but the liquefied koji made by lactic acid fermentation of the liquefied koji further enhances the suppressing effect.
健忘症抑制試験
メスの13週齢のICRマウスを用い、健忘症が抑制されるかどうかの試験を次のように行った。検体数は1群5匹で行った。試験はプラットホーム式水迷路装置(「水泳学習に適したマウスの系統とhemicholinium, Vasopressinなどの効果。簡単な水迷路学習装置による観察」山田健二、佐藤真理子、床井淳子、坪井實、長坂達夫(東京薬科大学)、薬学雑誌Vol.112(11)p824-831)を用いて、プラットホームへの到達時間でマウスの学習記憶能力を評価した。
Amnesia Inhibition Test Using a female 13-week-old ICR mouse, a test for whether forgetfulness was suppressed was performed as follows. The number of specimens was 5 groups. The test is based on a platform-type water maze device ("Effectiveness of mouse strain suitable for swimming learning and hemicholinium, Vasopressin, etc .. Observation with a simple water maze learning device" Kenji Yamada, Mariko Sato, Atsuko Tomoi, Atsushi Tsuboi, Tatsuo Nagasaka (Tokyo) The learning and memory ability of the mice was evaluated by the time to reach the platform using the Pharmaceutical University) and the Journal of Pharmaceutical Sciences Vol. 112 (11) p824-831).
マウスがスタート地点からプラットホームまで到達するのにかかった時間を測定し、これを獲得試行とする。獲得試行として、1日3回ずつ4日間連続でマウスを遊泳させて、マウスにプラットホームの位置を学習させた。その結果、到達時間は短縮されてほぼ一定値に収束した。 The time taken for the mouse to reach the platform from the starting point is measured, and this is taken as an acquisition attempt. As an acquisition trial, the mouse was allowed to swim three times a day for four consecutive days to allow the mouse to learn the platform position. As a result, the arrival time was shortened and converged to a substantially constant value.
獲得試行が終了した後のフォーマット済みのマウスに対して、胃ゾンデでコントロール区では蒸留水を10ml/kgを、被験区では乳酸発酵液化粕を3000mg/kgを強制経口投与した。蒸留水又は乳酸発酵液化粕投与の60分後にスコポラミンをマウスに2mg/kgを皮下投与して健忘症の誘発を行った。 After completion of the acquisition trial, the formatted mice were forcibly orally administered 10 ml / kg of distilled water in the control group and 3000 mg / kg of lactic acid fermentation liquor in the test group with a gastric sonde. At 60 minutes after administration of distilled water or lactic acid fermentation liquor, scopolamine was subcutaneously administered to mice at 2 mg / kg to induce amnesia.
スコポラミン投与の30分後に再び水迷路遊泳させて、学習記憶力の維持あるいは喪失を測定した(テスト試行)。その結果、コントロール区ではスコポラミン投与前と比べた到達時間(最後の獲得試行時のゴール到達時間と比べた到達時間)は有意に延長し(p<0.01)、健忘症モデルマウスの作成が認められた。発酵液化粕を事前に投与しておいた被験区では、コントロール区のテスト試行と比べて、到達時間は有意に抑制されて(p<0.05)、乳酸発酵液化粕投与による健忘症抑制効果が認められた。これらの結果を図4に示す。 After 30 minutes of scopolamine administration, the water maze was swam again, and the maintenance or loss of learning memory was measured (test trial). As a result, in the control group, the arrival time compared to before scopolamine administration (arrival time compared to the goal arrival time at the last acquisition trial) was significantly extended (p <0.01), and the creation of an amnesia model mouse was not possible. Admitted. Compared with the test trial in the control group, the arrival time was significantly suppressed (p <0.05) in the test group in which the fermented liquefied koji was administered in advance. Was recognized. These results are shown in FIG.
脱毛抑制試験
生後8日齢の幼若SDラットに対し、ブランク区では生理食塩水のみを腹腔内投与し、コントロール区と被験区には抗癌剤であるシトシンアラビノフラノシド(30mg/kg)を7日間続けて連続腹腔内投与した。1群を3匹で行った。その結果、コントロール区では抗癌剤投与により体毛のほぼ100%が脱落した脱毛モデル動物が得られた。被験区においては、乳酸発酵液化粕(500mg/kg)を抗癌剤と同時に腹腔内投与して、脱毛に対する影響を検討した。
Hair loss inhibition test For young SD rats 8 days old, only saline was administered intraperitoneally in the blank group, and cytosine arabinofuranoside (30 mg / kg), an anticancer drug, was administered in the control group and test group. Continuous intraperitoneal administration was continued for days. One group was performed with 3 animals. As a result, in the control group, a hair loss model animal was obtained in which almost 100% of the hair was removed by administration of the anticancer agent. In the test area, lactic acid fermentation liquefied koji (500 mg / kg) was intraperitoneally administered simultaneously with the anticancer agent to examine the effect on hair loss.
その結果、抗癌剤を投与していないブランク区では7日間で完全に発毛した。抗癌剤を投与したコントロール区では7日間でほとんど発毛が見られなかったが、被験区である乳酸発酵液化粕を加えた区では抗癌剤を加えたにも関わらず、7日間でコントロール区よりも多い発毛が見られた。このことから、乳酸発酵液化粕を加えたことにより、脱毛の進行を抑制する傾向が見られることが分かった。その結果を表1に示す。 As a result, in the blank area where no anticancer agent was administered, the hair grew completely in 7 days. In the control group to which the anticancer agent was administered, almost no hair growth was observed in 7 days, but in the group to which the lactic acid fermentation liquor was added, which was the test group, 7 days, there were more than the control group in spite of the addition of the anticancer agent. Hair growth was seen. From this, it was found that there was a tendency to suppress the progression of hair loss by adding lactic acid fermentation liquefaction koji. The results are shown in Table 1.
Claims (12)
A hair loss inhibiting composition comprising as an active ingredient a health functional composition obtained by the method according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005294699A JP2007099731A (en) | 2005-10-07 | 2005-10-07 | Health functional composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005294699A JP2007099731A (en) | 2005-10-07 | 2005-10-07 | Health functional composition |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2007099731A true JP2007099731A (en) | 2007-04-19 |
Family
ID=38027011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005294699A Pending JP2007099731A (en) | 2005-10-07 | 2005-10-07 | Health functional composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2007099731A (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010051311A (en) * | 2008-07-31 | 2010-03-11 | Niigata Prefecture | Food and drink having antiallergic function and method for producing the same |
JP2011032186A (en) * | 2009-07-30 | 2011-02-17 | Kyoei Kagaku Kogyo Kk | Cosmetic |
JP2011126833A (en) * | 2009-12-18 | 2011-06-30 | Gekkeikan Sake Co Ltd | Autonomic nerve regulator |
JP2011148737A (en) * | 2010-01-22 | 2011-08-04 | Kyoei Kagaku Kogyo Kk | Skin whitening cosmetic |
KR101099921B1 (en) | 2010-02-11 | 2011-12-28 | (주)오그린월드앤터프라이즈 | Lactobacillus multiplier manufacturing method with improved flavor |
JP2019006701A (en) * | 2017-06-23 | 2019-01-17 | 丸善製薬株式会社 | Hair-growing agent, anti-obesity agent, cosmetic, and food/drink product |
JP7549923B2 (en) | 2017-06-23 | 2024-09-12 | 丸善製薬株式会社 | Hair restorers, cosmetics, and food and beverages |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5826726A (en) * | 1981-08-05 | 1983-02-17 | Hitachi Plant Eng & Constr Co Ltd | Powder feeding device |
JPS6359837A (en) * | 1986-08-29 | 1988-03-15 | Kobe Steel Ltd | Production of yogurt-like fermented food |
JP2003261456A (en) * | 2002-03-08 | 2003-09-16 | Howaizu:Kk | Brain aging-preventing agent |
JP2004313032A (en) * | 2003-04-14 | 2004-11-11 | Sadaji Yokoyama | Method for producing functional raw material |
JP2005239686A (en) * | 2004-02-27 | 2005-09-08 | Pharma Foods International Co Ltd | Body fat combustion promotion composition and food or medicine containing the same |
-
2005
- 2005-10-07 JP JP2005294699A patent/JP2007099731A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5826726A (en) * | 1981-08-05 | 1983-02-17 | Hitachi Plant Eng & Constr Co Ltd | Powder feeding device |
JPS6359837A (en) * | 1986-08-29 | 1988-03-15 | Kobe Steel Ltd | Production of yogurt-like fermented food |
JP2003261456A (en) * | 2002-03-08 | 2003-09-16 | Howaizu:Kk | Brain aging-preventing agent |
JP2004313032A (en) * | 2003-04-14 | 2004-11-11 | Sadaji Yokoyama | Method for producing functional raw material |
JP2005239686A (en) * | 2004-02-27 | 2005-09-08 | Pharma Foods International Co Ltd | Body fat combustion promotion composition and food or medicine containing the same |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010051311A (en) * | 2008-07-31 | 2010-03-11 | Niigata Prefecture | Food and drink having antiallergic function and method for producing the same |
JP2011032186A (en) * | 2009-07-30 | 2011-02-17 | Kyoei Kagaku Kogyo Kk | Cosmetic |
JP2011126833A (en) * | 2009-12-18 | 2011-06-30 | Gekkeikan Sake Co Ltd | Autonomic nerve regulator |
JP2011148737A (en) * | 2010-01-22 | 2011-08-04 | Kyoei Kagaku Kogyo Kk | Skin whitening cosmetic |
KR101099921B1 (en) | 2010-02-11 | 2011-12-28 | (주)오그린월드앤터프라이즈 | Lactobacillus multiplier manufacturing method with improved flavor |
JP2019006701A (en) * | 2017-06-23 | 2019-01-17 | 丸善製薬株式会社 | Hair-growing agent, anti-obesity agent, cosmetic, and food/drink product |
JP2022001590A (en) * | 2017-06-23 | 2022-01-06 | 丸善製薬株式会社 | Anti-obesity agent, cosmetic product, and food and drink products |
JP7227647B2 (en) | 2017-06-23 | 2023-02-22 | 丸善製薬株式会社 | Anti-obesity agents, cosmetics, and food and drink |
JP7549923B2 (en) | 2017-06-23 | 2024-09-12 | 丸善製薬株式会社 | Hair restorers, cosmetics, and food and beverages |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nasri et al. | Fermented protein hydrolysates: biological activities and applications | |
Lee et al. | Biomolecules from municipal and food industry wastes: an overview | |
Martinez-Villaluenga et al. | Bioactive peptides in fermented foods: Production and evidence for health effects | |
KR101408568B1 (en) | Process of fermented food containing enzyme by using mixed Aspergillus oryzae and lactic acid bacteria | |
JP4795841B2 (en) | Germinated barley fermented product | |
JP2018531036A6 (en) | New strain derived from traditional fermented food with excellent enzyme-producing ability and method for producing cereal fermented enzyme food using the same | |
JP2018531036A (en) | New strain derived from traditional fermented food with excellent enzyme-producing ability and method for producing cereal fermented enzyme food using the same | |
JP2022188206A (en) | Skin external composition | |
KR102302933B1 (en) | Preparation of fermented garlic mixture and manufacturing method of composition effective for cardiovascular disease | |
JP7406839B2 (en) | Skin external preparations | |
JP7489688B2 (en) | Skin preparations | |
JP2012087091A (en) | Cosmetic | |
JP2007099731A (en) | Health functional composition | |
JP5144112B2 (en) | Brain protectant | |
JP2003192695A (en) | Angiotensin I converting enzyme inhibitor | |
JP5463075B2 (en) | Method for producing tyrosinase activity inhibitor | |
CA2642539C (en) | Agent for preventing arteriosclerosis, agent for suppressing vascular intimal thickening and agent for improving vascular endothelial function | |
JP5940871B2 (en) | Soybean rice bran fermented composition and method for producing the same, antihypertensive composition and food and drink | |
JP2009196949A (en) | Angiotensin converting enzyme-inhibiting peptide | |
JP2003047456A (en) | Fermented vinegar and method for producing the same | |
KR20130112401A (en) | Method for manufacturing ferment extract from rice bran and cosmetic compositions containing threrof | |
KR20080000008A (en) | Situation mushroom vinegar with antihypertensive activity | |
RU2572623C2 (en) | Peptide | |
KR101516764B1 (en) | A composition containing Humulus japonicus extracts for preventing or treating liver disease or atherosclerosis | |
JP4783576B2 (en) | Antihypertensive |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080805 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110913 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120403 |